Abstract:Abstract Background Porcine circovirus type 2 (PCV2) is the causative agent of postweaning multisystemic wasting syndrome, and is associated with a number of other diseases. PCV2 is widely distributed in most developed swine industries, and is a severe economic burden. With an eye to developing an effective, safe, and convenient vaccine against PCV2-associated diseases, we have constructed a recombinant Bacillus subtilis strain ( B. subtilis -Cap) that expresses the PCV2 capsid protein (Cap). Methods Electroporation of a plasmid shuttle vector encoding the PCV2 Cap sequence was use to transform Bacillus subtilis . Flow cytometry was used to evaluate in vitro bone marrow derived dendritic cell (BM-DC) maturation and T cell proliferation induced by B. subtilis -Cap. Orally inoculated piglets were used for in vivo experiments; ELISA and western blotting were used to evaluate B. subtilis -Cap induced PCV2-specific IgA and IgG levels, as well as the secretion of cytokines and the expression of Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9). Results We evaluated the immune response to B. subtilis -Cap in vitro using mouse BM-DCs and in vivo using neonatal piglets orally inoculated with B. subtilis -Cap. Our results showed that the recombinant B. subtilis -Cap activated BM-DCs, significantly increased co-stimulatory molecules (CD40 and CD80) and major histocompatibility complex II, and induced allogenic T cells proliferation. Piglets immunized with B. subtilis -Cap had elevated levels of PCV2-specific IgA in the mucosal tissues of the digestive and respiratory tract, and PCV2-specific IgG in serum ( P < 0.05 or P < 0.01). Ileal immunocompetent cells, such as the IgA-secreting cells ( P < 0.01), intestinal intraepithelial lymphocytes (IELs) ( P < 0.01), CD3 + T lymphocytes ( P < 0.01) and CD4 + T lymphocytes ( P < 0.01) increased significantly in the B. subtilis -Cap immunized piglets. Additionally, B. subtilis -Cap inoculation resulted in increased the expression of TLR2 and TLR9 ( P < 0.01), and induced the secretion of cytokines IL-1β, IL-6, interferon-γ, and β-defensin 2 ( P < 0.01). Conclusions We constructed a prototype PCV2 vaccine that can be administered orally and elicits a more robust humoral and cellular immunity than inactivated PCV2. B. subtilis -Cap is a promising vaccine candidate that is safe, convenient, and inexpensive. Further in vivo research is needed to determine its full range of efficacy in pigs. Graphical abstract

Model of Piglet Infected by Streptococcus suis Type 2 and Immune Protective Trial of Vaccine against Swine Streptococcosis

Establishment of Infection Model for Streptococcus Suis Serotype 2 in Mini-Pig

Progress Toward the Development of a Vaccine Against Streptococcus suis Capsular Type 2

Study on Immunological Examination in Blood with Two Streptococcus Suis Serotype 2 Strains Infection in Miniature Swine Model

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Genetic and Virulence Characterization of Streptococcus Suis Type 2 Isolates from Swine in the Provinces of Zhejiang and Henan, China

TLR4 Agonist Combined with Trivalent Protein JointS of <i>Streptococcus suis</i> Provides Immunological Protection in Animals

Potent Protective Immune Responses to Senecavirus Induced by Virus-Like Particle Vaccine in Pigs

Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2

Immune response induced by a Streptococcus suis multi-serotype autogenous vaccine used in sows to protect post-weaned piglets

Histopathological and Cytopathological Findings in Minipigs Infected with Streptococcus Suis Serotype 2

Location and Dynamic Distribution of Serotype 2 Streptococcus Suis in Tissues and Organs of Infected SPF Pigs

A protein-based subunit vaccine with biological adjuvants provides effective protection against Pasteurella multocida in pigs

Efficacy evaluation of a bivalent subunit vaccine against classical swine fever virus and porcine circovirus type 2

Immune Responses in Piglets Infected with Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus

Serodynamic Analysis of the Piglets Born from Sows Vaccinated with Modified Live Vaccine or E2 Subunit Vaccine for Classical Swine Fever

An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs

Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus

Preliminary Evaluation of Protective Efficacy of Inactivated Senecavirus A on Pigs

Protective efficacy of a candidate live attenuated vaccine derived from the SD-R strain of lineage 1 porcine reproductive and respiratory syndrome virus against a lethal challenge with HP-PRRSV HuN4 in piglets

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System